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Results One and 4 months after CSWT, sublingual nitrate 
use decreased from 10/week to 2/week (p < 0.01) and the 
angina symptoms diminished from CCS class III to CCS 
class II (p < 0.01). This clinical improvement was accompa-
nied by an improved myocardial uptake on stress myocardi-
al scintigraphy (54.2 ± 7.7 % to 56.4 ± 9.4 %, p = 0.016) and 
by increased exercise tolerance at 4-month follow-up (from 
7.4 ± 2.8 to 8.8 ± 3.6 min p = 0.015). No clinically relevant 
side effects were observed.
Conclusion CSWT improved symptoms and reduced isch-
aemia burden in patients with end-stage coronary artery 
disease without relevant side effects. The study provides a 
solid basis for a randomised multicentre trial to establish 
CSWT as a new treatment option in end-stage coronary ar-
tery disease.
Keywords Angina, stable · Myocardial ischaemia · 
Radionuclide imaging · Echocardiography ·  
Shock Waves, Ultrasonic
Introduction
Despite advances in medical and invasive revascularisation 
therapy a substantial number of patients show progression 
to end-stage ischaemic coronary artery disease with chronic 
refractory angina symptoms and no further revascularisa-
tion options [1]. Long-term mortality in patients with refrac-
tory angina who are not candidates for revascularisation is 
low. Over 70 % of patients with refractory angina survive 9 
years from the time of diagnosis. Therapeutic options for 
this growing population should therefore focus on chest 
pain relief and improved quality of life [2]. For these ‘no-
option patients’ [3], novel therapeutic strategies have been 
developed to improve both quality of life and prognosis, 
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Abstract
Background Cardiac shockwave therapy (CSWT) might 
improve symptoms and decrease ischaemia burden by stim-
ulating collateral growth in chronic ischaemic myocardium. 
This prospective study was performed to evaluate the feasi-
bility and safety of CSWT.
Methods We included 33 patients (mean age 70 ± 7 years, 
mean left ventricular ejection fraction 55 ± 12 %) with end-
stage coronary artery disease, chronic angina pectoris and 
reversible ischaemia on myocardial scintigraphy. CSWT 
was applied to the ischaemic zones (3–7 spots/session, 100 
impulses/spot, 0.09 mJ/mm2) in an echocardiography-guid-
ed and ECG-triggered fashion. The protocol included a total 
of 9 treatment sessions (3 treatment sessions within 1 week 
at baseline, and after 1 and 2 months). Clinical assessment 
was performed using exercise testing, angina score (CCS 
class), nitrate use, myocardial scintigraphy, and cardiac 
magnetic resonance (CMR) 1 and 4 months after the last 
treatment session.
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cannot be controlled by a combination of medical therapy, 
angioplasty and coronary bypass surgery. The presence of 
reversible myocardial ischaemia should be clinically estab-
lished to be the cause of the symptoms. Chronic is defined 
as a duration of more than 3 months [30].
Shockwave therapy
During a 4-year period, 55 patients with chronic refractory 
angina and end-stage coronary artery disease were referred 
to our institution. Twenty-two patients were excluded, 
mostly because of absence of reversible ischaemia or 
unstable symptoms. Thirty-three patients fulfilled the inclu-
sion criteria (reversible ischaemia on myocardial perfusion 
scintigraphy (SPECT), stable ischaemia-related symptoms 
for more than 3 months prior to the CSWT initiation with-
out a change in medication) and were included and treated 
with shockwave therapy [20] after further revascularisation 
options had been evaluated for each patient and individually 
found to be non-viable by the Heart Team of our institution.
The outpatient shockwave treatment protocol included 
3 treatments per week at 0, 1 and 2 months resulting in a 
total of 9 treatment sessions. Per session, 3–7 different spots 
were treated. With the patient in a supine position, CSWT 
was applied to the ischaemic zones (100 impulses/spot, 
energy flux 0.09 mJ/mm2 using the CardiospecTM device 
(Medispec Ltd, Germantown, USA) in an echocardiogra-
phy-guided and ECG-triggered fashion. Briefly, the Cardio-
specTM device creates shockwaves using an electrohydraulic 
method. An electric discharge within a water filled applica-
tor evaporates a small portion of water that generates shock-
waves. The shockwaves are reflected and focused, with 
a focus size of 8 mm width and 25 mm depth, by means 
of an applicator to the zone of myocardial ischaemia. The 
ischaemic regions were detected by SPECT and during 
treatment located by ultrasound using a transthoracic echo-
cardiography transducer mounted on a special holder on the 
shockwave applicator (Fig. 1).
Clinical assessment of the patients was performed by 
exercise testing (modified Bruce protocol), angina score 
(CCS class), nitrate use, echocardiography and SPECT at 
baseline (prior to first treatment session), and 1 month and 
4 months after the last treatment session. Cardiac magnetic 
resonance imaging (CMR) was performed for safety rea-
sons in the first 8 patients at baseline, 1 and 4 months.
The safety of the shockwave therapy was assessed with 
continuous rhythm monitoring as well as blood pressure 
measurements during the intervention. Further, repeated 
electrocardiograms and echocardiography during and after 
the treatment were performed. Blood samples were taken to 
exclude potential myocardial damage. The clinical status of 
the patient was assessed and the skin controlled for burns or 
erythema immediately and 1 h after the procedure.
which include enhanced external counter-pulsation [4], spi-
nal cord stimulation [5], therapeutic angiogenesis [6], cor-
onary sinus intervention [7] and newer drugs [1]. Cardiac 
shockwave therapy (CSWT) is a novel treatment strategy 
targeting angiogenesis with concomitant improvement of 
the local microcirculation.
A shockwave is a single pressure pulse with a short 
(< 1 msec) positive spike with an amplitude up to 100 MPa 
followed by a lower amplitude tensile part lasting several 
microseconds [8]. The highly localised physical forces of 
shockwaves are used to disintegrate urolithiasis in urology 
[9] and, with lower shockwave energy, in orthopaedics to 
induce neovascularisation, and improve local perfusion and 
tissue regeneration [10, 11]. Clinical studies with statisti-
cally significant positive outcomes have been performed for 
urolithiasis [9], calcifying tendinitis [10], plantar fasciitis 
[12], epicondylitis of the lateral humerus [11], delayed heal-
ing of bone fractures [13], and diabetic and vascular ulcers 
[14, 15].
In predominantly animal model studies, the following 
effects of shockwave therapy have been observed: Cavi-
tation (rapid formation and collapse of vapour pockets in 
and outside cells with the formation of jet streams and free 
radicals) [16], thermal and chemical effects [17], molecular 
biological and cellular changes [13], and hyperstimulation 
analgesia [18]. These effects result in complex changes in 
tissue such as the formation of new bone, neo-angiogenesis 
and nerve stimulation.
Pre-clinical studies and limited clinical data suggest a 
positive effect of very low energy shockwaves (0.09 mJ/
mm2) on myocardial ischaemia and left ventricular function 
[19–29]. Upregulation of vascular endothelial growth fac-
tor (VEGF) mRNA and protein expression are likely to be 
responsible for the increasing capillary density observed in 
ischaemic myocardium treated by shockwaves [20].
The current study was performed to evaluate the feasibil-
ity and safety of CSWT in patients with chronic refractory 
angina pectoris and to provide initial insight into the persis-
tence of any clinical effects during mid-term follow-up of 
up to 4 months.
Methods
The study was approved by the Maastricht University Medi-
cal Centre Ethics Committee and written informed consent 
was obtained from all participants.
Definition of refractory angina
Refractory angina pectoris is a chronic condition character-
ised by the presence of angina caused by coronary insuf-
ficiency in the presence of coronary artery disease, which 
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two experienced observers, a nuclear cardiologist (SV) or 
an experienced nuclear medicine physician (BB or CdP), 
blinded to the clinical data. The visual interpretation of 
perfusion images was based on short-axis and vertical and 
horizontal long-axis tomograms [32] divided into a 17-seg-
ment model, according to the American Heart Association 
[33]. Supporting the visual interpretation, a semi-quantita-
tive analysis was also performed: each segment was scored 
automatically based on a 5-point scoring system (0, normal 
uptake; 1, mild decreased uptake; 2, moderately decreased 
uptake; 3, severely decreased uptake; 4, absence of uptake), 
as previously described [34, 35]. The sum of the stress 
scores of all segments (SSS) and the sum of the rest scores 
of all segments (SRS) were determined from these values. A 
summed difference score (SDS) was calculated as the differ-
ence between SSS and SRS. SDS > 1 was defined as revers-
ible perfusion defect indicating ischaemia.
Scintigraphy results were divided into two categories: (i) 
negative, defined as having homogenous radioactive distri-
butions in myocardium, on both stress and rest scans, and 
SDS = 0; (ii) positive, defined as reversible and fixed per-
fusion defects. Reversible perfusion defects were consid-
ered the segments with a decreased tracer uptake at stress 
but with partial improvement or complete normalisation of 
tracer uptake at rest. Fixed pattern showed that localised 
segments of decreased perfusion were unchanged between 
the stress and rest images. Reversible perfusion defects with 
SDS > 1 were considered to represent myocardial ischaemia, 
whereas fixed perfusion defects were considered to be myo-
cardial scar. The inter-observer variability was found to be 
< 10 %. For evaluation of the effect of CSWT quantitative 
polar maps were constructed of the stress and rest perfu-
sion, using the Autoquant/QPS software package (Philips 
Medical Systems, Andover, MA, USA). This map displays 
the myocardial perfusion as raw counts. The pixel with the 
maximum raw count is set to the maximum colour scale 
brightness and corresponds to a value of 100. Values of the 
segmental counts corresponded to the average pixel value 
in that segment. Values of corresponding segments between 
stress and rest images were compared, stratifying between 
treated and untreated segments (Fig. 2).
Cardiac magnetic resonance
Patients were examined with a 1.5 T MR scanner (Gyroscan 
Intera, Philips Medical Systems, Best, the Netherlands) as 
previously described [36]. Cine images were acquired for 
functional analysis using a steady-state free precession 
sequence (TR/TE 3.8/1.9 ms, flip angle 50°) in 2-, 3- and 
4-chamber long axis and contiguous short axis views. Stan-
dard late gadolinium enhancement images were acquired 
to evaluate the presence of myocardial infarction (breath 
hold multislice T1-weighted 3D inversion-recovery gra-
Echocardiography
Before therapy, and 1 and 4 months after shockwave therapy, 
a complete echocardiographic examination was performed 
to evaluate left ventricular systolic and diastolic function 
and size, segmental wall motion and valve function using 
Sonos 5500 ultrasound systems with S3-1 (1–3 MHz) trans-
thoracic transducers or IE33 ultrasound systems with S5-1 
(1–5 Mhz) transducers (Philips Medical Systems, Andover, 
MA, USA). In addition, image quality in supine position 
was evaluated since shockwave therapy can only be per-
formed in the supine position. During treatment, the isch-
aemic zones were placed in the middle of the sector scan.
As described above, diagnostic echocardiography was 
also performed during shockwave therapy to steer the 
shockwave beam to the myocardial regions of interest, as 
previously defined by SPECT.
Myocardial perfusion imaging
SPECT was performed by a one-day protocol, using either 
Tl-201 (111 MBq) or Tc-99 m-sestamibi (270 MBq after 
stress, 1000 MBq at rest) [31]. Per patient, the same stress 
protocol was used in all 3 tests (modified Bruce treadmill 
exercise, 0.5 mg/kg body weight persantin IV, or both). 
Acquisition was performed using 60 or 64 projections over 
180º (RAO 45º to LPO 45º) with non-circular orbit (Phil-
ips Skylight dual-headed gamma-camera, Philips Medical 
Systems, Andover, MA, USA). Acquisition time was 30 s 
per projection during stress acquisition and 20 s during rest 
acquisition. Reconstruction into tomographic trans-axial 
images was done using filtered back projection with no scat-
ter or attenuation correction applied. Analysis of perfusion 
images utilised the Quantitative Perfusion SPECT (QPS) 
software (QPS, Cedar-Sinai, Los Angeles, CA) installed 
with the custom-developed normal database. An experi-
enced technologist performed processing, while the semi-
quantitative visual judgment was made by the consensus of 
 Fig. 1 The shockwave applica-
tor mounted in a holder together 
with a standard echocardiogra-
phy transducer. Echocardiogra-
phy is used to locate predefined 
ischaemic regions and to guide 
the focus of the shockwave 
applicator
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eters were analysed to detect or exclude myocardial damage 
as a potential side effect of CSWT: serum creatinine kinase, 
(high sensitive) troponin T, aspartate aminotransferase and 
alanine aminotransferase.
Statistical methods
Statistical analysis was performed using SPSS software 
(SPSS, Inc., Chicago, IL, USA). Continuous variables with 
no/mild skew were presented as mean ± SD, skewed mea-
sures as median. Discrete variables were summarised as fre-
quencies and percentages. Differences were assessed using 
a paired sample t-test for normally distributed data or Wil-
coxon signed rank two related sampled analyses for other 
distributions.
Results
The study group consisted of 33 patients (27 males, mean 
age 69.7 years). The baseline characteristics of the patient 
population are summarised in Table 1. The treatment dura-
tion was 28 ± 8 min (mean ± SD) per session depending on 
the acoustic window, heart rate and number of spots treated 
(3–7 spots per session).
CSWT was well tolerated without major side effects. 
Transient dizziness shortly after the first treatment ses-
sion was reported from 4 patients. Creatinine kinase 
(106 ± 52 U/l) or TnT levels were not elevated following 
the treatment sessions in any of the patients. The electrocar-
diograms did not show any significant changes after treat-
ment. No arrhythmias were observed and no clinical signs 
of dyspnoea or coughing as a sign of lung contusion were 
noticed. No skin erythema or burns were observed. There 
were no changes in medication during the treatment and the 
follow-up.
Clinical benefit of CSWT
Following CSWT, the clinical status improved significantly: 
The use of sublingual nitrates decreased from a median of 
10 per week (range 1–25) pre-CSWT to 2 per week (range 
0–20) at 1 month and to 2 per week (range 0–7) at 4 months 
post-CSWT (p < 0.01). Simultaneously, angina complaints 
decreased by at least one CCS class in 25 patients at 1 month 
and in all but two patients at 4 months after CSWT (p < 0.01) 
(Table 2). The exercise tolerance slightly improved during 
follow-up (from 7.4 ± 2.8 to 8.3 ± 3.9 and to 8.8 ± 3.6 min, 
p = 0.015).
dient-echo sequence, slice thickness 12 mm, gap − 6 mm, 
TR/TE 4.2/1.3 ms, flip angle 15°, FOV 400 mm, resolu-
tion 256 × 256) 10 min after intravenous administration of 
0.2 mmol/kg Gadolinium-DTPA (Magnevist, Bayer Scher-
ing AG, Berlin, Germany). Inversion times were adjusted to 
null normal myocardium (200–300 ms).
CMR images were analysed with the CAAS MRV 3.0 
software (Pie Medical Imaging, Maastricht, the Nether-
lands). Areas of myocardial infarction were visually assessed 
on late enhancement images. If present, areas were quanti-
fied by planimetry using a signal cut-off of > 2 SD above the 
mean signal intensity of remote myocardium in the same 
slice and expressed as a percentage of total LV mass.
Clinical chemistry analysis
Blood samples were taken after the second treatment ses-
sion from all patients and the following laboratory param-
Fig. 2 Quantitative polar map (17 segments) displaying the myocardi-
al perfusion as the raw counts based on myocardial scintigraphy analy-
sis. The pixel with the maximum raw count is set to the maximum co-
lour scale brightness and corresponds to a value of 100. The numbers 
correspond with the average ‘raw’ pixel value in the related segments
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disease, the so called ‘no-option patients’. The beneficial 
effects were observed in the absence of detectable relevant 
side effects. Our study demonstrates an improvement of the 
clinical status of the patients undergoing CSWT.
Moreover, our study provides mechanistic insight into 
the improvement of regional myocardial perfusion fol-
lowing CSWT, and thereby provides a solid basis for the 
increased exercise tolerance of these patients during follow-
up of up to 4 months. The SPECT data suggest that at least 
part of the positive effect might be due to improved perfu-
sion in the treated ischaemic zones at stress. Consistent with 
this observation and as expected, no changes in resting per-
fusion were detectable in treated and untreated myocardial 
areas nor in the stress perfusion of untreated areas.
These results confirm the preliminary findings of Fuku-
moto et al., who investigated 9 patients with end-stage coro-
nary artery disease [19]. The limited improvement of stress 
perfusion by about 2 % for the whole group is in agreement 
with the proposed mechanism of angiogenesis on the micro-
vascular level. This positive effect on myocardial perfusion 
was also found by Kaller et al. [28] and is in line with the 
results of Vasyuk et al. on a hibernating myocardium and 
ischaemic heart failure after shock wave treatment [22]. The 
improvement of left ventricular systolic function found in 
their study and in the study by Zuoziene et al. [26] was not 
confirmed by our results and results of Alluni et al. [27] and 
Clinical benefit of CSWT correlates with improved 
regional myocardial perfusion
Regional myocardial perfusion revealed a significant 
decrease of ischaemia burden in treated regions following 
CSWT demonstrated by SPECT on stress images after 1 
month (p = 0.037) and 4 months (p = 0.016) (Table 2, Fig. 3). 
As expected, myocardial perfusion at rest was unaltered in 
treated and untreated areas before and after CSWT. Also, left 
ventricular ejection fraction was not found to be different 
before and after the shockwave treatment. We investigated a 
subgroup of 8 patients for scar formation using gadolinium 
delayed enhancement CMR. This substudy did not reveal 
a change in scar tissue volume following CSWT (Table 2).
Discussion
The main finding of our study is that CSWT therapy is 
capable of improving ischaemic symptoms and reducing 
ischaemia burden in patients with end-stage coronary artery 
Table 1 Baseline characteristics of treated patients (n = 33)
Age (years; mean, SD) 69.7 ± 8
Male 27 (82 %)
Body mass index (mean, SD) 29 ± 4.6
Heart rate (beats/min; mean, SD) 67 ± 11
Systolic blood pressure (mmHg; mean, SD) 132 ± 19
Diastolic blood pressure (mmHg; mean, SD) 77 ± 10
Smoking 8 (24 %)
Positive family history for coronary disease 11 (33 %)
Diabetes mellitus 15 (46 %)
Hypertension 25 (76 %)
Hypercholesterolaemia 31 (94 %)
Chronic obstructive pulmonary disease 4 (12 %)
Three-vessel disease 28 (85 %)
Two-vessel disease 5 (15 %)
History of PCI 18 (55 %)
History of multiple PCIs 12 (36 %)
History of CABG 25 (76 %)
History of repeated CABG 6 (18 %)
History of stroke 5 (15 %)
Peripheral vascular disease 8 (24 %)
Aspirin 21 (64 %)
Clopidogrel 10 (30 %)
Oral anticoagulation 8 (24 %)
Nitrates 30 (91 %)
Beta-blockers 28 (85 %)
Calcium antagonists 26 (79 %)
ACE inhibitor 12 (36 %)
AT II antagonist 7 (21 %)
Insulin 6 (18 %)
Oral antidiabetic agents 10 (30 %)
Fig. 3 Perfusion scintigraphy at stress; comparison 4 month post 
CSWT with baseline (prior to CSWT). X axis: baseline and 4-month 
follow–up. Y axis: relative percentage of perfusion of treated segment
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